View Prescribing Information
Patient Information
Healthcare Professionals Site
Visit IncyteCARES

Become an Ambassador for Jakafi

Share Your Story

You have a unique story to tell and sharing it could make a meaningful difference to other people who are discovering what’s possible with Jakafi® (ruxolitinib). The Ambassadors for Jakafi program is for eligible patients taking Jakafi. By becoming an Ambassador for Jakafi, you may be able to help others by:

video play button icon

Telling your story through a video,

icon of 2 chat bubbles

Sharing your thoughts within an educational setting,

 

or

book icon

Providing your opinion about patient educational materials.

Share Your Experiences to Help Others

Please complete the following fields.

It is OK to contact me via text message at this number
Which of the following applies to you/your loved one?
The best time to contact me is

Consent for Use of Personal Information
By clicking Sign Up below, I certify that I am 18 years of age or older and authorize Incyte Corporation (“Incyte”) and its agents to use my registration information provided above (my “information”) to contact me via mail, telephone (including leaving a voicemail that mentions the Ambassadors for Jakafi Program), Internet-based or electronically (eg, Internet) or otherwise in order to provide education and ongoing support services related to product, disease and other areas of interest. I understand that I may at any time revoke my consent to be contacted for any of these purposes by opting out from future communications from Incyte by calling the Ambassadors for Jakafi Program at 1-877-647-9205 or emailing . I also understand that the information I provide may be combined with that of other registrants to create aggregated, anonymized data and to use and share only the anonymized data for any legitimate business purpose. Learn more about how Incyte processes your personal information at Privacy Policy.

I understand that the personal information I provide on this website may be used by Incyte Corporation, or other companies acting on its behalf, to contact me via mail, via telephone, in electronic format, via Internet-based delivery or otherwise in the future. I authorize Incyte Corporation and its agents to contact me via mail, telephone (including leaving a voicemail that mentions opportunities to share my story with Incyte), Internet-based or electronically (e.g., Internet) or otherwise in the future and use and release information about me only for the purposes of (i) providing education and ongoing support services to me related to treatment, disease, and other areas of interest; and (ii) gathering feedback on my therapy treatment and/or disease state. I understand that some of my information may be provided anonymously and used in an individual or aggregated form for other legitimate purposes by Incyte. Neither Incyte Corporation nor anyone working on behalf of Incyte will sell or rent personal information collected on this site. I understand that reasonable efforts will be made to keep my information private even though my information disclosed under this authorization may not be protected under federal and state privacy laws. My personal information may also be used for the purposes described in the Privacy Policy. I understand that from time to time, Incyte Corporation's Privacy Policy may change and that I should check the website for the most recent version. I understand that I should check the website for the most recent version of Incyte Corporation’s Legal Notices.

U.S. State Law Consent to Health Data Use for Marketing Purposes

I consent to Incyte collecting, using and disclosing my health data for the following purposes:

  • To conduct marketing activities, including market research activities, and to communicate with me regarding products and services that may be of interest to me.

Incyte uses the following for marketing purposes:

  • Health data – my name, gender, date of birth, contact information and information relating to my health condition or treatment.

I understand that Incyte is seeking my consent to collect, use and disclose health data to market products and services to me and I understand that Incyte may use my health data to contact me by email for the above purposes. I also understand that Incyte will not sell my health data to third parties, but Incyte may disclose my health data to Incyte’s vendors only for Incyte’s business purposes. Finally, I understand that I may withdraw my consent to the use of my health data for marketing purposes by calling 855-446-2983 or visiting http://www.incyte.com/privacy-policy. I understand that this consent will remain in effect for one year, unless and until I revoke) it in writing prior to that time.

By signing the consent, I agree that these entities may use my Health Information to administer the Program or as permitted or required by applicable privacy laws. I permit such use for one year after the dates I sign the consent, unless and until I revoke (i.e., take back) it in writing prior to that time.

By indicating above, I am indicating that I am legally authorized to consent and that I am providing my consent as the patient or the patient’s legal guardian for Incyte to collect, process and disclose my health data I provide for the purposes described within the Consent above.

Expand

 

Collapse

 
 
 

INDICATIONS AND USAGE

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech.

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing.

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.